University Hospitals is first in Cleveland to offer new targeted therapy for brain tumors

From University Hospitals: A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman Cancer Center is the first to offer this to patients with brain tumors in Cleveland.

Andrew E. Sloan, M.D.

Andrew Sloan, MD, Director of the Brain Tumor Program at University Hospitals Seidman Cancer Center, said, “GammaTile has the potential to allow patients to have their radiation and surgery simultaneously, allowing patients to get back to their families and their lives several months earlier than with other methods.” Dr. Sloan is a member of the Case Comprehensive Cancer Center's Developmental Therapeutics and Cancer Imaging Research Programs.

Read the full release on the GammaTile Therapy